PROGRAM CHAIR
Aditya Bardia, MD, MPH, FASCO
Program Director, Breast Medical Oncology
Assistant Chief (Translational Research), Division of Hematology-Oncology
Professor of Medicine, Geffen School of Medicine, University of California Los Angeles
Director of Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, CA
PROGRAM OVERVIEW
This online enduring activity is designed to equip medical oncologists, advanced practice providers, and other members of the oncology team with insights on the role of TROP-2-directed antibody-drug conjugates (ADCs) in treating patients with triple-negative breast cancer (TNBC) and HR+/HER2-negative breast cancer. This activity will focus on evaluating key clinical data with TROP-2-directed ADCs in this setting; identifying high risk populations who can benefit most from these therapies; managing adverse events; and integrating TROP-2-directed ADCs into individualized treatment for patients with breast cancer.
TARGET AUDIENCE
This activity is intended for medical oncologists, advanced practice providers, and nurses who treat patients with triple-negative breast cancer (TNBC) and HR+ breast cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Identify high risk patient populations with metastatic TNBC who will realize clinical benefit with TROP-2 directed ADC treatment.
- Create individualized treatment plans including TROP-2 ADC therapy for patients with TNBC and HR+ breast cancer using knowledge of safety and efficacy data.
- Describe strategies for identifying and managing treatment related toxicities of TROP-2 directed ADC therapy.
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Aditya Bardia, MD | Consulting Fees | AstraZeneca/Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Merck, Menarini, Novartis, Pfizer and Sanofi |
| Contracted Research | AstraZeneca/Daiichi Sankyo, Eli Lilly, Genentech, Gilead, Merck, Menarini, Novartis, Pfizer and Sanofi |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Senior VP of Operations for Med Learning Group, has nothing to disclose.
- Sarah Milano, RN, MSN has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Shpetim Karandrea, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: February 03, 2025
EXPIRATION DATE: February 03, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
